Educational Webinars

ERS/EULAR guideline on CTD-ILD - Session two: treatment and patient-centred care - 25 FEBRUARY, 2026

ERS/EULAR guideline on CTD-ILD - Session two: treatment and patient-centred care - 25 FEBRUARY, 2026

To take part in this event, you must register in advance.

You are registered to this event

25 February, 2026 | Online
17:00-18:00 CET

 

Chairs: Dr Anna Maria Hoffmann-Vold (Oslo, Norway), Prof. Katerina Antoniou (Heraklion, Greece)

Speakers: Prof. Dr Oliver Distler (Zurich, Switzerland), Prof. Dr Elisabetta Renzoni (London, United Kingdom), Dr Jens Vikse (Stavanger, Norway)

 

Fees: Free for ERS members / €10 for non-members
Find out more about becoming a member

Please note: non-members will need to create a free myERS account to register for this activity.

Overview

Treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD) is rapidly evolving and the new guideline provides critical, graded recommendations on pharmacologic and non-pharmacologic management. This webinar addresses an urgent need to educate clinicians on the new treatment algorithm, the use of immunosuppressants and antifibrotics, and the importance of shared decision-making, including the patient's perspective.

Topics:

  • Evidence-based treatment recommendations and the therapeutic algorithm.
  • Pharmacologic management: immunosuppression and antifibrotic therapy.
  • Patient-focused care and shared decision-making.
  • Managing complex treatment scenarios and disease progression.

Format

One-hour webinar structured as follows:

  • Opening remarks - Introduction by Chairs (5 min)
  • Presentation 1: Treatment Options & Recommendations - Oliver Distler (13 min)
  • Presentation 2: The Clinician's Commentary: Weighing Risks & Benefits - Elisabetta Renzoni (13 min)
  • Presentation 3: Navigating Treatment Dilemmas: A Case-Based Approach - Jens Vikse (13 min)
  • Live Q&A and round table - moderated by Chairs (15 min)
  • Wrap-up (1 min)

Learning outcomes

Following this webinar, participants will be able to:

  • Evaluate the evidence-based treatment options for different CTD-ILD subtypes.
  • Formulate a personalised treatment plan based on the new guideline's therapeutic algorithm.
  • Integrate patient preferences and values into the treatment decision-making process.

CME credit

An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.

What is a webinar?

A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Login guidelines

More information will be communicated in due course.

  • Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
  • Check Central European Time.
  • To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
  • Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

Diseases/methods:

  • Interstitial lung diseases

Target audience

  • Pulmonologists
  • Rheumatologists
  • Internists
  • Trainees/Fellows
  • Healthcare Professionals involved in the long-term care of CTD-ILD patients.